Gilles Collin
Overview
Explore the profile of Gilles Collin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
773
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coppee R, Chenane H, Bridier-Nahmias A, Tcherakian C, Catherinot E, Collin G, et al.
Virus Res
. 2022 Oct;
323:198950.
PMID: 36181977
Human respiratory syncytial virus (RSV) is responsible of lower respiratory tract infections which may be severe in infants, elderly and immunocompromised adults. Europe and North-American countries have observed a massive...
2.
Richetta C, Subra F, Malet I, Leh H, Charpentier C, Corona A, et al.
J Virol
. 2022 Jun;
96(14):e0067622.
PMID: 35758669
Integration of the reverse-transcribed genome is a critical step of the retroviral life cycle. Strand-transfer inhibitors (INSTIs) used for antiretroviral therapy inhibit integration but can lead to resistance mutations in...
3.
Ferre V, Lebourgeois S, Chenane H, Menidjel R, Masson C, Collin G, et al.
J Infect
. 2022 Mar;
84(6):834-872.
PMID: 35278483
No abstract available.
4.
Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, et al.
AIDS
. 2022 Mar;
36(8):1055-1060.
PMID: 35262531
Objective: Treatment of multidrug-resistant HIV-2 is an emerging issue, because of the rapid selection of mutations at time of virological failure and the low number of antiretrovirals active on HIV-2....
5.
Lebourgeois S, Chenane H, Houhou-Fidouh N, Menidjel R, Ferre V, Collin G, et al.
Front Cell Infect Microbiol
. 2022 Jan;
11:792202.
PMID: 34976868
Since its emergence in China at the end of 2019, SARS-CoV-2 has rapidly spread across the world to become a global public health emergency. Since then, the pandemic has evolved...
6.
Lebourgeois S, Menidjel R, Chenane H, Ferre V, Collin G, Damond F, et al.
J Infect
. 2021 Nov;
84(3):418-467.
PMID: 34808243
No abstract available.
7.
Gounant V, Ferre V, Soussi G, Charpentier C, Flament H, Fidouh N, et al.
J Thorac Oncol
. 2021 Nov;
17(2):239-251.
PMID: 34798306
Introduction: Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2)...
8.
Le Hingrat Q, Collin G, Damond F, Peytavin G, Lebourgeois S, Ghosn J, et al.
J Antimicrob Chemother
. 2021 Nov;
77(2):409-412.
PMID: 34741606
Background: HIV-2 resistance to integrase strand-transfer inhibitors (INSTIs) is characterized by two main pathways: (i) mutations at codons 143, 148 and155; and (ii) amino acid insertion after integrase codon 231...
9.
Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E
Vaccines (Basel)
. 2021 Oct;
9(10).
PMID: 34696248
Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of "prime-boost" (heterologous) vaccination regimens including a first administration of a viral...
10.
Ferre V, Lebourgeois S, Menidjel R, Collin G, Chenane H, Guindi M, et al.
J Infect
. 2021 Oct;
84(2):248-288.
PMID: 34600020
No abstract available.